NICE is unable to make a recommendation about the use in the NHS of lenalidomide (Revlimid) with bortezomib and dexamethasone for untreated multiple myeloma
NICE is unable to make a recommendation about the use in the NHS of pomalidomide (Imnovid) with bortezomib and dexamethasone for relapsed or refractory myeloma
NICE is unable to make a recommendation about the use in the NHS of bezlotoxumab (Zinplava) for preventing recurrent Clostridium difficile infection in adults
NICE is unable to make a recommendation about the use in the NHS of brentuximab vedotin (Adcetris) for untreated advanced Hodgkin lymphoma in adults
Evidence-based recommendations on bisphosphonates (alendronic acid; ibandronic acid; risedronate sodium; zoledronic acid) for treating osteoporosis in adults
Evidence-based recommendations on fluocinolone acetonide intravitreal implant (Iluvien) for chronic diabetic macular oedema that has inadequately responded to
NICE is unable to make a recommendation about the use in the NHS of ramucirumab (Cyramza) for treating unresectable hepatocellular carcinoma after sorafenib
Evidence-based recommendations on Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (excessive salivation and drooling) in adults
Evidence-based recommendations on lenalidomide (Revlimid) for the treatment of multiple myeloma in people who have received at least 2 prior therapies
Evidence-based recommendations on blinatumomab (Blincyto) for treating Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia
Evidence-based recommendations on benralizumab (Fasenra) for treating severe eosinophilic asthma (SEA; elevated levels of eosinophils in blood) in adults
Evidence-based recommendations on dacomitinib (Vizimpro) for locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (NSCLC) in adults
Evidence-based recommendations on ribociclib (Kisqali) for hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer in adults
Evidence-based recommendations on idelalisib (Zydelig) for follicular lymphoma that has not responded to 2 prior lines of treatment in adults
Evidence-based recommendations on cemiplimab (Libtayo) for treating locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC) in adults
Evidence-based recommendations on letermovir (Prevymis) for preventing cytomegalovirus (CMV) disease after a stem cell transplant in adults
Evidence-based recommendations on sodium zirconium cyclosilicate (Lokelma) for treating hyperkalaemia (elevated blood potassium levels) in adults
Evidence-based recommendations on pembrolizumab (Keytruda) with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (NSCLC)
Evidence-based recommendations on risankizumab (Skyrizi) for treating moderate to severe plaque psoriasis in adults
Evidence-based recommendations on dapagliflozin (Forxiga) with insulin for type 1 diabetes not controlled by insulin therapy alone in adults with a BMI of at
Evidence-based recommendations on lenalidomide (Revlimid) for myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality
Evidence-based recommendations on ocrelizumab (Ocrevus) for treating primary progressive multiple sclerosis (MS) in adults
Evidence-based recommendations on nusinersen (Spinraza) for treating spinal muscular atrophy in children and adults
Evidence-based recommendations on lenalidomide (Revlimid) plus dexamethasone for previously untreated multiple myeloma in adults
Evidence-based recommendations on lenalidomide (Revlimid) plus dexamethasone for multiple myeloma after 1 treatment with bortezomib in adults
Evidence-based recommendations on fluocinolone acetonide intravitreal implant (Iluvien) for treating recurrent non-infectious uveitis in adults
Evidence-based recommendations on olaparib (Lynparza) for treating BRCA mutation-positive, advanced ovarian, fallopian tube or primary peritoneal cancer